We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
1
IFP Advisors
Florida
$10.2K -$9.12K -223 -47%
BlackRock
2
BlackRock
New York
– -$545M -13,536,964 Closed
ACA
3
Avoro Capital Advisors
New York
– -$492M -12,222,222 Closed
Morgan Stanley
4
Morgan Stanley
New York
– -$404M -10,042,399 Closed
State Street
5
State Street
Massachusetts
– -$275M -6,844,990 Closed
UBS Group
6
UBS Group
Switzerland
– -$250M -6,206,681 Closed
Vanguard Portfolio Management
7
Vanguard Portfolio Management
Pennsylvania
– -$217M -5,404,559 Closed
Vanguard Capital Management
8
Vanguard Capital Management
Pennsylvania
– -$192M -4,768,944 Closed
DTC
9
Deep Track Capital
Connecticut
– -$182M -4,532,374 Closed
Point72 Asset Management
10
Point72 Asset Management
Connecticut
– -$168M -4,183,918 Closed
RI
11
RTW Investments
New York
– -$148M -3,685,045 Closed
HI
12
HBK Investments
Texas
– -$143M -3,550,000 Closed
Geode Capital Management
13
Geode Capital Management
Massachusetts
– -$83.5M -2,075,075 Closed
JP Morgan Chase
14
JP Morgan Chase
New York
– -$35M -2,047,927 Closed
Goldman Sachs
15
Goldman Sachs
New York
– -$79.7M -1,980,144 Closed
Balyasny Asset Management
16
Balyasny Asset Management
Illinois
– -$77.1M -1,917,501 Closed
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
– -$53.7M -1,338,995 Closed
TAL
18
TIG Advisors LLC
New York
– -$50.4M -1,252,986 Closed
Toronto Dominion Bank
19
Toronto Dominion Bank
Ontario, Canada
– -$49.7M -1,236,436 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
20
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$48.4M -1,202,100 Closed
Fidelity International
21
Fidelity International
Bermuda
– -$45.9M -1,140,000 Closed
KC
22
Kryger Capital
United Kingdom
– -$44.3M -1,100,000 Closed
SFM
23
Soros Fund Management
New York
– -$42.5M -1,056,000 Closed
CLGM
24
Capitolis Liquid Global Markets
New York
– -$40.8M -1,013,500 Closed
WP
25
Woodline Partners
California
– -$39.3M -976,175 Closed
1
2 3 4 5

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.